Abalance Corporation

3856.T
Software - Application
2026/08/21 Updated
Market Cap: $50.9M (¥8.1B)
Stock Price: $2.69 (¥427)
Exchange Rate: 1 USD = ¥158.98

Abalance Corporation 2026 Fiscal Year Q2 ( Interim Period ) Financial Summary

For the second quarter of the 2026 fiscal year, net sales were 56,242 million yen, operating income 5,503 million yen, ordinary income 5,348 million yen, and net income attributable to owners of the parent 6,179 million yen. Special gains were recorded, including foreign exchange gains of 696 million yen and gains on sale of fixed assets of 4,306 million yen. Segment highlights: Solar panel manufacturing 51,255 million yen, Green energy 4,667 million yen, others 319 million yen. In the US market, while affected by tariffs (AD/CVD), the company is expanding the supply chain with cell production commencing in Ethiopia and increasing supply from the new US plant to strengthen the supply chain.

Importance:
Page Updated: August 19, 2026
IR Disclosure Date: August 19, 2026

Key Figures

  • Sales: 56,242 million yen
  • Operating income: 5,503 million yen
  • Ordinary income: 5,348 million yen

AI要約

Overview of Results

For the interim period, net sales were 56,242 million yen, operating income 5,503 million yen, ordinary income 5,348 million yen, and net income attributable to owners of the parent 6,179 million yen. As special gains, foreign exchange gains of 696 million yen and fixed asset sale gains of 4,306 million yen were recorded, while certain figures in the financial summary were revised. By segment, Solar panel manufacturing accounted for 51,255 million yen, Green energy 4,667 million yen, and others 319 million yen. In the US market, despite tariff impacts, the company is advancing supply chain strengthening by starting cell production in Ethiopia and expanding supply from a new US plant.

Outlook and Risks

Risks driven by tariff trends in the US market and geopolitical developments remain. The company aims to strengthen its earnings base through cost competitiveness of Ethiopian cell production and expanded production at its US plant. Interim period's financial position shows an improved equity ratio of 22.2%, and cash and cash equivalents have increased. As of the earnings announcement, the annual dividend forecast is undecided, and any revision to full-year earnings guidance remains as previously announced.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Abalance Corporation

Company overview · Stock price · Financial data · All IR

View company page →